Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

155.73 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗
Discover Neurocrine Biosciences (NBIX), a neuroscience leader with strong growth, high profitability, and a positive technical breakout setup. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million. 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology ↗
Neurocrine Biosciences (NBIX) offers solid growth and strong profitability at a reasonable valuation. This biotech stock fits the "affordable growth" strategy for long-term investors. 
Via Chartmill
News headline image
Where Neurocrine Biosciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screened as a Strong Growth Stock with Bullish Technical Setup ↗
Neurocrine Biosciences (NBIX) is a strong growth stock with accelerating revenue, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Analyst Expectations For Neurocrine Biosciences's Future ↗
 
Via Benzinga
News headline image
Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation ↗
Neurocrine Biosciences (NBIX) is a top GARP stock with strong growth, solid profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine (NBIX) Q2 Revenue Jumps 17% ↗
Via The Motley Fool
News headline image
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals ↗
Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and fair valuation, making it a top pick for affordable growth investors. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns ↗
Neurocrine Biosciences (NBIX) beat Q2 2025 revenue and EPS estimates but stock fell 8.6% amid investor concerns over guidance. INGREZZA sales grew 17% YoY. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential ↗
Neurocrine Biosciences (NBIX) shows strong growth potential with solid fundamentals, high profitability, and a bullish technical breakout pattern in the biotech sector. 
Via Chartmill
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts ↗
 
Via Benzinga
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation ↗
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks in the biotech... 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High profitability, no debt, and a potential breakout add to its appeal. 
Via Chartmill
News headline image
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stock ↗
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth in the biotech sector. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth, profitability, and a bullish technical setup, making it a stock worth watching for growth investors. 
Via Chartmill
News headline image
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation ↗
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
News headline image
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target ↗
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes. 
Via Benzinga
News headline image
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug ↗
The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands. 
Via Investor's Business Daily
News headline image
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Stock Surges After-Hours On Upbeat Q1, Reaffirmed Ingrezza Outlook — Retail Buzz Soars ↗
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.